BofA raises Illumina stock target to USD 168.00

Published on 10/17/2026 at 19:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Illumina reports results on October 29, 2026. Illumina stock last stood at USD 262.54 on October 16, 2026, down 2.01 percent versus the Nasdaq close.

Analyst target and upcoming results

BofA lifted its Illumina target from USD 140.00 to USD 168.00 on October 9, 2026.
Illumina will report third-quarter 2026 results on October 29, 2026.
Illumina stock last stood at USD 262.54 on October 16, 2026 at 4:00 p.m. ET, down 2.01 percent versus the Nasdaq close.
Illumina had a USD 39.6 billion market capitalization and a 48.98 price-to-earnings ratio on October 16, 2026.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin beim Pipettieren im Genomiklabor — Illumina Inc. zeigt US4523271090 in dokumentarischer Schwarzweiß-Reportage einer Wissenschaftlerin beim Pipettieren im Labor, Illustration mit AI erstellt.

BofA raised its Illumina price target from USD 140.00 to USD 168.00 on October 9, 2026, while retaining an Underperform rating, Markets Insider reported. The target is 36.01 percent below Illumina's USD 262.54 last traded price on October 16, 2026.

Results date sets the next marker

Illumina is scheduled to publish its third-quarter 2026 results after the Nasdaq close on October 29, 2026. The company also scheduled an analyst call for 4:30 p.m. ET that day, according to its investor release dated October 8, 2026, Illumina.

Price sits below the yearly high

Illumina last traded at USD 262.54 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 2.01 percent from the prior close of USD 267.93. The stock's 52-week range was USD 94.00 to USD 309.35, putting the latest price 15.13 percent below the high. Trading volume reached 2,488,968 shares, versus an average of 2,758,440 shares, a gap of 9.78 percent.

Valuation and industry comparison

Illumina had a market capitalization of USD 39.6 billion and a price-to-earnings ratio of 48.98 on October 16, 2026. The comparison shows a wide spread across genomics tools: Pacific Biosciences of California (Nasdaq, USD) fell 11.73 percent, carried a price-to-earnings ratio of minus 4.02 and had a USD 537.7 million market capitalization. 10x Genomics (Nasdaq, USD) fell 3.49 percent, had a price-to-earnings ratio of minus 118.41 and a USD 9.1 billion market capitalization.

Comparison with peers

Illumina Inc.: minus 2.01 percent, P/E 48.98, market capitalization USD 39.6 billion
Pacific Biosciences of California (Nasdaq, USD): minus 11.73 percent, P/E minus 4.02, market capitalization USD 537.7 million
10x Genomics (Nasdaq, USD): minus 3.49 percent, P/E minus 118.41, market capitalization USD 9.1 billion

What the target says about valuation

BofA's USD 168.00 target sits below the latest Nasdaq price, while the October 29 results date provides the next scheduled company-specific checkpoint. For investors, the contrast between the target and the market price is the clearest valuation signal in the available figures.

Price and the next checkpoint

Illumina's last Nasdaq quote stood at USD 262.54 on October 16, 2026 at 4:00 p.m. ET, down 2.01 percent versus the Nasdaq close of October 15, 2026 at USD 267.93. The company is due to release third-quarter results on October 29, 2026.